|
| [51] | S. Loosen, M. F. Schulze-Hagen, P. Bruners, F. Tacke, C. Trautwein, C. K. Kuhl, T. Lüdde, C. Roderburg,
"Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies", Cancers, vol. 11, no. 10, 2019, pp. 1503.
|
| [50] | S. Sutti, S. Bruzzì, F. Heymann, A. Liepelt, O. Krenkel, A. Toscani, N. Ramavath, D. Cotella, E. Albano, F. Tacke,
"CX3CR1 Mediates the Development of Monocyte-Derived Dendritic Cells during Hepatic Inflammation", Cells, vol. 8, no. 9, 2019, pp. 1099.
|
|
| [49] | M. Bartneck, C. Koppe, V. Fech, K. T. Warzecha, M. Kohlhepp, S. Huss, R. Weiskirchen, C. Trautwein, T. Lüdde, F. Tacke,
"Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion", Cellular and Molecular Gastroenterology and Hepatology, vol. 11, no. 2, 2020, pp. 327–347.
|
| [48] | F. Benz, A. Bogen, M. Praktiknjo, C. Jansen, C. Meyer, A. Wree, M. Demir, S. Loosen, M. Vucur, R. Schierwagen, F. Tacke, J. Trebicka, C. Roderburg,
"Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis", PLOS ONE, vol. 15, no. 4, 2020, pp. e0231701.
|
| [47] | L. Buendgens, E. Yagmur, A. Ginsberg, R. Weiskirchen, T. Wirtz, S. A. Jhaisha, A. Eisert, T. Lüdde, C. Trautwein, F. Tacke, A. Koch,
"Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up", Mediators of inflammation, vol. 2020, 2020, pp. 7184803.
|
| [46] | A. Guillot, F. Tacke,
"The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA‐223 to Macrophages", Hepatology, vol. 71, no. 2, 2020, pp. 749–751.
|
| [45] | A. Guillot, M. S. Kohlhepp, A. Bruneau, F. Heymann, F. Tacke,
"Deciphering the Immune Microenvironment on A Single Archival Formalin-Fixed Paraffin-Embedded Tissue Section by An Immediately Implementable Multiplex Fluorescence Immunostaining Protocol", Cancers, vol. 12, no. 9, 2020, pp. 2449.
|
| [44] | J. Hundertmark, F. Tacke,
"How effective are nonalcoholic fatty liver disease models for drug discovery?", Expert opinion on drug discovery, vol. 15, no. 11, 2020, pp. 1237–1240.
|
| [43] | J. Lambrecht, L. A. van Grunsven and F. Tacke,
"Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis", Expert opinion on pharmacotherapy, vol. 21, no. 13, 2020, pp. 1637–1650.
|
| [42] | S. Lefere, L. Devisscher and F. Tacke,
"Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis", Expert opinion on investigational drugs, vol. 29, no. 2, 2020, pp. 89–92.
|
| [41] | S. Lefere, T. Püngel, J. Hundertmark, C. Penners, A. K. Frank, A. Guillot, K. de Muynck, F. Heymann, V. Adarbes, E. Defrêne, C. Estivalet, A. Geerts, L. Devisscher, G. Wettstein, F. Tacke,
"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages", Journal of hepatology, vol. 73, no. 4, 2020, pp. 757–770.
|
| [40] | A. Liepelt, P. Hohlstein, H. Gussen, J. Xue, A. C. Aschenbrenner, T. Ulas, L. Bündgens, K. T. Warzecha, M. Bartneck, T. Lüdde, C. Trautwein, J. L. Schultze, A. Koch, F. Tacke,
"Differential Gene Expression in Circulating CD14+ Monocytes Indicates the Prognosis of Critically Ill Patients with Sepsis", Journal of Clinical Medicine, vol. 9, no. 1, 2020, pp. 127.
|
| [39] | I. Lurje, L. Hammerich and F. Tacke,
"Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer", International journal of molecular sciences, vol. 21, no. 19, 2020, pp. 7378.
|
| [38] | J. C. Mossanen, T. U. Jansen, J. Pracht, A. Liepelt, L. Bündgens, C. Stoppe, A. Goetzenich, T. Simon, R. Autschbach, G. Marx, F. Tacke,
"Elevated circulating CD14++CD16+ intermediate monocytes are independently associated with extracardiac complications after cardiac surgery", Scientific reports, vol. 10, 2020, pp. 947.
|
| [37] | T. Püngel, S. De Vos, J. Hundertmark, M. Kohlhepp, N. Guldiken, P. Pujuguet, M. Auberval, F. Marsais, K. F. Shoji, L. Saniere, C. Trautwein, T. Lüdde, P. Strnad, R. Brys, P. Clément-Lacroix, F. Tacke,
"The medium-chain fatty acid receptor gpr84 mediates myeloid cell infiltration promoting steatohepatitis and fibrosis", Journal of Clinical Medicine, vol. 9, no. 4, 2020, pp. 1140.
|
| [36] | T. Püngel, F. Tacke,
"Editorial: prevalence, progression rates and mortality predictors of non-alcoholic fatty liver disease reflected by German statutory health insurance data", Alimentary pharmacology & therapeutics, vol. 52, no. 8, 2020, pp. 1412–1413.
|
| [35] | K. C. Reimer, A. Wree, C. Roderburg, F. Tacke,
"New drugs for NAFLD", Hepatology international, vol. 14, no. 1, 2020, pp. 8–23.
|
| [34] | C. Roderburg, A. Wree, M. Demir, M. Schmelzle, F. Tacke,
"The role of the innate immune system in the development and treatment of hepatocellular carcinoma", Hepatic Oncology, vol. 7, no. 1, 2020, pp. 11 Seiten.
|
| [33] | S. Torres, Z. Abdullah, M. J. Brol, C. Hellerbrand, M. Fernandez, R. Fiorotto, S. Klein, P. Königshofer, C. Liedtke, S. Lotersztajn, Y. A. Nevzorova, R. Schierwagen, T. Reiberger, F. E. Uschner, F. Tacke, R. Weiskirchen, J. Trebicka,
"Recent Advances in Practical Methods for Liver Cell Biology", International journal of molecular sciences, vol. 21, no. 6, 2020, pp. 2027.
|
| [32] | T. Wirtz, S. H. Loosen, L. Buendgens, B. Kurt, S. Abu Jhaisha, P. Hohlstein, J. F. Brozat, R. Weiskirchen, T. Lüdde, F. Tacke, C. Trautwein, C. Roderburg, A. Koch,
"Low Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients", Diagnostics, vol. 10, no. 8, 2020, pp. 574.
|
| [31] | T. Wirtz, L. Buendgens, R. Weiskirchen, S. H. Loosen, N. Haehnsen, T. Puengel, S. Abu Jhaisha, J. F. Brozat, P. Hohlstein, G. Koek, A. Eisert, R. Mohr, C. Roderburg, T. Lüdde, C. Trautwein, F. Tacke, A. Koch,
"Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients", Diagnostics, vol. 10, no. 11, 2020.
|
|
| [30] | A. Bruneau, J. Hundertmark, A. Guillot, F. Tacke,
"Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases", Frontiers in medicine, vol. 8, 2021, pp. 725390.
|
| [29] | K. M. Detjen, R. Otto, Y. Giesecke, L. Geisler, P. Riemer, H. Jann, C. Grötzinger, C. Sers, A. Pascher, T. Lüdde, U. Leser, B. Wiedenmann, M. Sigal, F. Tacke, C. Roderburg, L. Hammerich,
"Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms", Cancers, vol. 13, no. 17, 2021, pp. 4463.
|
| [28] | B. Kurt, L. Bündgens, T. Wirtz, S. H. Loosen, M. Schulze-Hagen, D. Truhn, J. F. Brozat, S. Abu Jhaisha, P. Hohlstein, G. Koek, R. Weiskirchen, C. Trautwein, F. Tacke, K. Hamesch, A. Koch,
"Serum Perilipin 2 (PLIN2) Predicts Multiple Organ Dysfunction in Critically Ill Patients", Biomedicines, vol. 9, no. 9, 2021, pp. 1210.
|
| [27] | J. Lambrecht, F. Tacke,
"Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease", Frontiers in immunology, vol. 11, 2021, pp. 634409.
|
| [26] | J. Lambrecht, M. Porsch-Özçürümez, J. Best, F. Jost-Brinkmann, C. Roderburg, M. Demir, F. Tacke, R. Mohr,
"The APAC Score", Journal of Clinical Medicine, vol. 10, no. 15, 2021, pp. 3392.
|
| [25] | S. H. Loosen, C. Roderburg, P. H. Alizai, A. A. Roeth, S. M. Schmitz, M. Vucur, M. Luedde, D. Schöler, P. Paffenholz, F. Tacke, C. Trautwein, T. Lüdde, U. P. Neumann, T. F. Ulmer,
"Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases", Diagnostics, vol. 11, no. 11, 2021, pp. 1999.
|
| [24] | S. H. Loosen, V. van den Bosch, J. Gorgulho, M. Schulze-Hagen, J. Kandler, M. S. Jördens, F. Tacke, C. Loberg, G. Antoch, T. Brümmendorf, U. P. Neumann, C. K. Kuhl, T. Lüdde, C. Roderburg,
"Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy", Journal of Clinical Medicine, vol. 10, no. 7, 2021, pp. 1361.
|
| [23] | S. H. Loosen, J. Gorgulho, M. S. Jördens, M. Schulze-Hagen, F. Beier, M. Vucur, A. T. Schneider, C. Koppe, A. Mertens, J. N. Kather, F. Tacke, V. Keitel, T. H. Brümmendorf, C. Roderburg, T. Lüdde,
"Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy", Frontiers in oncology, vol. 11, 2021, pp. 646883.
|
| [22] | K. Müller, H. Honcharova-Biletska, C. Koppe, M. Egger, L. K. Chan, A. T. Schneider, L. Küsgens, F. Böhm, Y. Boege, M. E. Healy, J. Schmitt, S. Comtesse, M. Castoldi, C. Preisinger, M. Szydlowska, E. Focaccia, N. Gaisa, S. H. Loosen, S. Jörs, F. Tacke, C. Roderburg, V. Keitel, J. G. Bode, P. Boor, R. J. Davis, T. Longerich, F. Geisler, M. Heikenwalder, A. Weber, M. Vucur, T. Lüdde,
"JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging", Proceedings of the National Academy of Sciences of the United States of America, vol. 118, no. 12, 2021, pp. e2007194118.
|
| [21] | M. Peiseler, F. Tacke,
"Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma", Cancers, vol. 13, no. 4, 2021, pp. 730.
|
| [20] | M. Peiseler, F. Tacke,
"An Unexpected Line of Defense", Hepatology, vol. 74, no. 5, 2021, pp. 2888–2890.
|
| [19] | C. Roderburg, S. H. Loosen, J. Bednarsch, P. H. Alizai, A. A. Roeth, S. M. Schmitz, M. Vucur, M. Luedde, P. Paffenholz, F. Tacke, C. Trautwein, T. F. Ulmer, U. P. Neumann, T. Lüdde,
"Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma", International journal of molecular sciences, vol. 22, no. 12, 2021, pp. 6569.
|
| [18] | B. Rolles, J. Gorgulho, M. Tometten, C. Roderburg, M. Vieri, A. Abels, M. Vucur, F. Heymann, F. Tacke, T. H. Brümmendorf, T. Lüdde, F. Beier, S. H. Loosen,
"Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy", Frontiers in oncology, vol. 11, 2021, pp. 729207.
|
| [17] | S. Roohani, F. Tacke,
"Liver Injury and the Macrophage Issue", International journal of molecular sciences, vol. 22, no. 14, 2021, pp. 7249.
|
| [16] | A. Schippers, J. Hübel, F. Heymann, T. Clahsen, S. Eswaran, S. Schlepütz, R. Püllen, N. Gaßler, K. Tenbrock, F. Tacke, N. Wagner,
"MAdCAM-1/α4β7 Integrin-Mediated Lymphocyte/Endothelium Interactions Exacerbate Acute Immune-Mediated Hepatitis in Mice", Cellular and Molecular Gastroenterology and Hepatology, vol. 11, no. 4, 2021, pp. 1227–1250.el.
|
| [15] | M. F. Schulze-Hagen, C. Roderburg, T. H. Wirtz, M. S. Jördens, L. Bündgens, S. Abu Jhaisha, P. Hohlstein, J. F. Brozat, P. Bruners, C. Loberg, C. K. Kuhl, C. Trautwein, F. Tacke, T. Lüdde, S. H. Loosen, A. Koch,
"Decreased Bone Mineral Density Is a Predictor of Poor Survival in Critically Ill Patients", Journal of Clinical Medicine, vol. 10, no. 16, 2021, pp. 3741.
|
| [14] | F. Tacke, R. Weiskirchen,
"Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis", Annals of translational medicine, vol. 9, no. 8, 2021, pp. 729.
|
| [13] | Y. Wen, J. Lambrecht, C. Ju, F. Tacke,
"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities", Cellular & molecular immunology, vol. 18, no. 1, 2021, pp. 45–56.
|
|
| [12] | A. Bruneau, A. Guillot and F. Tacke,
"Macrophages in cholangiopathies", Current opinion in gastroenterology, vol. 38, no. 2, 2022, pp. 114–120.
|
| [11] | J. Hundertmark, H. Berger and F. Tacke, Single Cell RNA Sequencing in NASH, New York, NY: Humana Press, 2022, pp. 181–202.
|
| [10] | S. H. Loosen, T. Essing, M. Jördens, A. Koch, F. Tacke, W. T. Knoefel, J. Bode, C. Roderburg, T. Lüdde,
"Current epidemiological trends and in-hospital mortality of acute pancreatitis in Germany: a systematic analysis of standardized hospital discharge data between 2008 and 2017", Zeitschrift für Gastroenterologie, vol. 60, no. 03, 2022, pp. 310–319.
|
| [9] | T. Puengel, B. Weber, T. Wirtz, L. Buendgens, S. H. Loosen, L. Geisler, B. Özdirik, H. Karim, S. A. Jhaisha, J. F. Brozat, P. Hohlstein, A. Eisert, E. Yagmur, C. Trautwein, F. Tacke, A. Koch,
"Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients", Diagnostics, vol. 12, no. 1, 2022, pp. 62.
|
| [8] | T. Puengel, S. Lefere, J. Hundertmark, M. Kohlhepp, C. Penners, F. Van de Velde, B. Lapauw, A. Hoorens, L. Devisscher, A. Geerts, S. Boehm, Q. Zhao, J. Krupinski, E. D. Charles, B. Zinker, F. Tacke,
"Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis", International journal of molecular sciences, vol. 23, no. 12, 2022, pp. 6696.
|
|
| [7] | A. Guillot, M. Winkler, M. Silva Afonso, A. Aggarwal, D. Lopez, H. Berger, M. S. Kohlhepp, H. Liu, B. Özdirik, J. Eschrich, J. Ma, M. Peiseler, F. Heymann, S. Pendem, S. Mahadevan, B. Gao, L. Diehl, R. Gupta, F. Tacke,
"Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression", Hepatology, vol. 78, no. 1, 2023, pp. 150–166.
|
| [6] | L. Hammerich, Y. Shevchenko, J. Knorr, W. Werner, A. Bruneau, F. Tacke,
"Resolving 31 colors on a standard 3‐laser full spectrum flow cytometer for immune monitoring of human blood samples", Cytometry / B, vol. 104, no. 5, 2023, pp. 367–373.
|
| [5] | M. S. Kohlhepp, H. Liu, F. Tacke, A. Guillot,
"The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer—Challenges and opportunities", Frontiers in molecular biosciences, vol. 10, 2023, pp. 1129831.
|
| [4] | T. Lan, A. Guillot and F. Tacke,
"Somatic mutant clone screening: scan for novel NASH target genes in mouse liver", Signal transduction and targeted therapy, vol. 8, no. 1, 2023, pp. 319.
|
| [3] | J. Otto, A. Verwaayen, C. Penners, J. Hundertmark, C. Lin, C. Kallen, D. Paffen, T. Otto, H. Berger, F. Tacke, R. Weiskirchen, Y. A. Nevzorova, M. Bartneck, C. Trautwein, R. Sonntag, C. Liedtke,
"Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice", Cell death & disease, vol. 14, no. 8, 2023, pp. 549.
|
| [2] | N. Torow, R. Li, T. C. A. Hitch, C. Mingels, S. Al Bounny, N. van Best, E. Stange, B. Simons, T. Maié, L. Rüttger, N. M. K. P. Gubbi, D. A. Abbott, A. Benabid, M. Gadermayr, S. Runge, N. Treichel, D. Merhof, S. P. Rosshart, N. Jehmlich, T. W. Hand, M. von Bergen, F. Heymann, O. Pabst, T. Clavel, F. Tacke, H. Lelouard, I. G. Costa, M. W. Hornef,
"M cell maturation and cDC activation determine the onset of adaptive immune priming in the neonatal Peyer’s patch", Immunity, vol. 56, no. 6, 2023, pp. 1220–1238,e1–e7.
|
|
| [1] | T. Puengel, F. Tacke,
"Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis", Liver international, vol. 44, no. 2, 2024, pp. 275–278.
|